Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.

Chang Gon KimNam Suk Sim Jeong Eun KimKum-Hee YunYoung Han LeeSeung Hyun KimWooyeol BaekYoon Dae HanSang Kyum KimJi Hyoung KimYoon Woo KohInkyung JungSu-Jin Shin Sun Young RhaJin-Hee AhnHyo Song Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Eribulin-gemcitabine combination therapy showed promising activity and an acceptable safety profile in patients with liposarcoma or leiomyosarcoma. Gene expression profiling with pathway enrichment analysis would have possibilities to have predictive value for survival outcome, necessitating further investigation to confirm.

Keyphrases

combination therapy
phase ii
clinical trial
open label
genome wide
phase iii
double blind
locally advanced
genome wide identification
placebo controlled
transcription factor
dna methylation
randomized controlled trial
squamous cell carcinoma
rectal cancer
newly diagnosed